medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-9-116-119medsovet-1965Research ArticleАЛЛЕРГОЛОГИЯ И ИММУНОЛОГИЯALLERGOLOGY AND IMMUNOLOGYАСИТ – РЕШЕНИЕ В ЛЕЧЕНИИ АЛЛЕРГИИASIT – A SOLUTION IN ALLERGY TREATMENTЦАРЕВC. В.TSAREVS. V.

д.м.н.

MD

Институт иммунологии ФМБА РоссииРоссияInstitute of Immunology of the Federal Medical and Biological Agency of RussiaRussian Federation20172107201709116119Copyright © ЦАРЕВ C.В., 20172017ЦАРЕВ C.В.TSAREV S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1965

В статье рассмотрено место и роль аллерген-специфической иммунотерапии в лечении аллергических заболеваний. Представлены механизм действия, показания, противопоказания, побочные эффекты аллерген-специфической иммунотерапии. Проведено сравнение различных методик проведения аллерген-специфической иммунотерапии. Показаны преимущества сублингвальной аллерген-специфической иммунотерапии в педиатрической практике. Представлены данные об эффективности и безопасности сублингвальной иммунотерапии поллиноза с сенсибилизацией к злаковым травам

This article discusses the place and role of an allergen-specific immunotherapy in the treatment of allergic diseases. It provides an action mechanism, indications for use, contraindications, and side effects of an allergen-specific immunotherapy. A comparison of different methodologies for an allergen-specific immunotherapy was made. The advantages of sublingual allergen-specificimmunotherapy in paediatric practice were demonstrated. Provides data on the efficiency and safety of pollinosis sublingual immunotherapy with sensitization to grass

аллерген-специфическая иммунотерапиясублингвальная иммунотерапияполлинозаллергический ринитallergen-specific immunotherapysublingual immunotherapypollinosisallergic rhinitisReferencesГущин И.С., Курбачева О.М. Аллерген-специфи ческая иммунотерапия атопических заболеваний. Пособие для врачей. М., 2002, 32 с.Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term(13-year) retrospective study in real life. Int Arch Allergy Immunol, 2007, 142: 70-78.Федеральные клинические рекомендации по проведению аллерген-специфической иммунотерапии. М.: РААКИ, 2013, 13 с.Jacobsen L, Wahn U, Bilo M. B. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clinical and Translational Allergy, 2012, 2: 8-10.Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol, 2012, 129: 929-34.Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol, 2012, 129: 929-34.Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy, 2015, 70(8): 897-909.Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy, 2015, 70(8): 897-909.WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy, 1998, 53(44): 1-42.WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy, 1998, 53(44): 1-42.Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling H-J, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy, 2006, 61(82): 1-20.Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling H-J, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy, 2006, 61(82): 1-20.Devillier Ph, Dreyfus J-F, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Medicine, 2014, 1, 12: 71-74.Devillier Ph, Dreyfus J-F, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Medicine, 2014, 1, 12: 71-74.Wahn V, Tabar A, Kuna P. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunolog, 2009, 123: 160-166.Wahn V, Tabar A, Kuna P. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunolog, 2009, 123: 160-166.Didier A, Worm M, Horak F. Sustained 3-yearefficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunology, 2011, 128: 559-566.Didier A, Worm M, Horak F. Sustained 3-yearefficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunology, 2011, 128: 559-566.Didier A, Malling H-J, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy, 2015, 5: 12.Didier A, Malling H-J, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy, 2015, 5: 12.Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. Allergy Clin. Immunol, 2015, 136(3): 556-68.Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. Allergy Clin. Immunol, 2015, 136(3): 556-68.

The authors declare that there are no conflicts of interest present.